1468-2982/asset/olbannercenter.gif?v=1&s=20a7a9478adbfd60cd3e454e0116e3cff73e5018)
1468-2982/asset/olbannerright.gif?v=1&s=51e39df9bb1801c829e25bd4aeac8d8bda5a9fb9)
Intractable eye pain: indication for triptans
Article first published online: 5 JUN 2002
DOI: 10.1046/j.1468-2982.2002.00342.x
1468-2982/asset/cover.gif?v=1&s=a27c0a401a66f4447a00fca21da3177bb07d2062 "Cephalalgia")
Additional Information
How to Cite
May, A., Gamulescu, M., Bogdahn, U. and Lohmann, C. (2002), Intractable eye pain: indication for triptans. Cephalalgia, 22: 195–196. doi: 10.1046/j.1468-2982.2002.00342.x
Publication History
- Issue published online: 5 JUN 2002
- Article first published online: 5 JUN 2002
- Received 14 December 2001, accepted 2 January 2002
- Abstract
- Article
- References
- Cited By
Keywords:
- Eye pain;
- photorefractive keratectomy;
- sumatriptan
Management of pain is difficult in many eye diseases. Particularly in patients undergoing surgical procedures, postoperative intractable pain is a major concern and severely influences the patient's comfort. We present 13 patients (eight male, five female, mean age 36 years) in whom sumatriptan, a highly selective 5-HT1B/1D agonist that is normally used as a specific anti-migraine drug, was used for the treatment of pain following photorefractive keratectomy (PRK). In two patients both eyes were operated on different days, resulting in a total of 15 operated eyes. A positive clinical response was achieved in all patients. In particular, in four patients, who received a second dose prophylactically 4 h following the first dose and before the recurrence of pain, we achieved excellent efficacy and stable control of pain. Further controlled studies are needed to investigate the usefulness of 5-HT1B/1D agonists in painful eye conditions.